Cancer Genetics (CGIX), an early-stage diagnostics company focused on developing and...

|About: Cancer Genetics, Inc. (CGIX)|By:, SA News Editor

Cancer Genetics (CGIX), an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to cancer treatment, lowers its IPO amount to 1.65M shares at an offering price of $10 to $12 per share. The company's previous filing was for 1.85M shares at the same price range.